WHO Issues Alert Over Critical Scarcity of Obesity Jabs

Under one in 10 people who could benefit from obesity jabs including Wegovy have access to them, warns the global health agency as it releases its first recommendations on the drugs.

Considering over a billion people worldwide now living with obesity, it is urging more widespread and fairer access to GLP-1 medication.

According to estimates, over two billion could be living with obesity by 2030 unless action is taken.

"Our new guidance affirms that obesity is a long-term condition that can be treated with thorough and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and logistical bottlenecks are key barriers to widespread availability to the treatments that can assist patients in reducing substantial weight, explains the agency.

GLP-1 Therapy Shortage

Even in the present most favorable scenario, the supply of such drugs would only suffice for around 100 million people – less than 10% of eligible patients, according to the health organization.

The recommendation encourages nations and manufacturers to increase access, through strategies such as licensing agreements.

Exclusive production rights on the active ingredient – the core ingredient of a leading brand – is scheduled to end in a number of nations in 2026.

The Way Obesity Jabs Function

These medications mimick a body's own hormone to slow digestion, curb appetite and increase feelings of fullness so individuals reduce food intake.

Individuals usually begin shedding pounds after several weeks of commencing the regular doses.

Research suggests people may put most of the weight back on after a year of discontinuing the drug, because their usual appetite return.

To be above a healthy weight raises your likelihood for contracting health problems, including diabetes, cardiovascular issues, brain attack, and certain cancers.

Excess weight concerns people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.